Yes, Genotropin (somatropin) is FDA-approved for treating adult growth hormone deficiency (GHD) in patients with either adult-onset or childhood-onset GHD.[1][2]
How Genotropin treats adult GHD
Genotropin is a recombinant human growth hormone that replaces deficient endogenous GH. In adults, it's indicated for confirmed GHD due to pituitary disease, hypothalamic disease, surgery, radiation, or trauma. Dosing starts low (e.g., 0.15–0.3 mg/day subcutaneously) and titrates based on IGF-1 levels, age, and sex, with monitoring for efficacy and safety.[1][3]
Difference from pediatric uses
While Genotropin is first known for pediatric GH deficiency, short stature, and conditions like Turner syndrome, its adult indication focuses on metabolic effects like reduced body fat, increased lean mass, improved bone density, and better lipid profiles. Replacement therapy doesn't restart linear growth in adults.[1][2]
Who qualifies and when to start
Diagnosis requires stimulated GH testing (e.g., insulin tolerance or arginine-GH stimulation) showing peak GH <5 ng/mL, plus low IGF-1. Therapy begins after pituitary evaluation rules out other hormone deficiencies. Guidelines from Endocrine Society recommend it for severe GHD; mild cases may not benefit enough to justify risks.[3][4]
Common side effects in adults
Patients report fluid retention (edema), joint/muscle pain, carpal tunnel syndrome, and insulin resistance. Rare risks include glucose intolerance or intracranial hypertension. Long-term use needs annual monitoring for malignancy or diabetes.[1][3]
Alternatives to Genotropin
Other somatropin brands like Norditropin, Humatrope, or Nutropin are also approved for adult GHD and are dosed similarly. Biosimilars (e.g., Omnitrope) offer lower-cost options with comparable efficacy. Non-GH therapies address symptoms indirectly via lifestyle or other hormones.[2][5]
Patent and availability details
Genotropin, made by Pfizer, faces generic competition post-patent expiry in various markets. U.S. patents on the delivery device expired around 2020, but formulation patents linger. Check DrugPatentWatch.com for expiry dates and challengers.[6]
[1] Genotropin Prescribing Information, Pfizer, 2023. https://labeling.pfizer.com/showlabeling.aspx?id=577
[2] FDA Approved Drug Products (Orange Book), somatropin listings. https://www.accessdata.fda.gov/scripts/cder/ob/
[3] Endocrine Society Clinical Practice Guideline: Evaluation and Treatment of Adult GHD, 2019. https://academic.oup.com/jcem/article/104/10/4103/5487919
[4] Pituitary Society Consensus: GH Testing in Adults, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502910/
[5] Omnitrope Prescribing Information, Sandoz, 2023. https://www.omnitrope.com/
[6] DrugPatentWatch.com, Genotropin patents. https://www.drugpatentwatch.com/p/tradename/GENOTROPIN